These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11911727)

  • 21. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
    Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E
    Arch Intern Med; 2000 Jun; 160(12):1781-7. PubMed ID: 10871971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [No chance for pain. Rofecoxib eases not only tooth extraction].
    MMW Fortschr Med; 2002 Jun; 144(26):48-9. PubMed ID: 12154476
    [No Abstract]   [Full Text] [Related]  

  • 23. A double-blind prospective comparison of rofecoxib vs ketorolac in reducing postoperative pain after arthroscopic knee surgery.
    Kim JT; Sherman O; Cuff G; Leibovits A; Wajda M; Bekker AY
    J Clin Anesth; 2005 Sep; 17(6):439-43. PubMed ID: 16171664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management.
    Joshi W; Connelly NR; Reuben SS; Wolckenhaar M; Thakkar N
    Anesth Analg; 2003 Jul; 97(1):35-8, table of contents. PubMed ID: 12818939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 29. Idiopathic paresthesia reaction associated with rofecoxib.
    Daugherty KK; Gora-Harper ML
    Ann Pharmacother; 2002 Feb; 36(2):264-6. PubMed ID: 11847946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
    Ann Intern Med; 2003 Oct; 139(7):I29. PubMed ID: 14530248
    [No Abstract]   [Full Text] [Related]  

  • 31. Aseptic meningitis associated with chronic sulindac use for osteoarthritis: a case report.
    Callen EC; Church CO; Patel M; Sikes TL
    Rheumatol Int; 2008 Feb; 28(4):391-3. PubMed ID: 17703306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M
    Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy with rofecoxib. Decreasing risk by controlled COX-2 inhibitor administration].
    MMW Fortschr Med; 2000 Nov; 142(48):64-5. PubMed ID: 11144940
    [No Abstract]   [Full Text] [Related]  

  • 36. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 37. [Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
    MMW Fortschr Med; 2003 Aug; 145(31-32):56-7. PubMed ID: 14524083
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical pharmacology of the selective COX-2 inhibitors].
    Burian M; Geisslinger G
    Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
    Oliw E; Wollheim FA
    Lakartidningen; 2000 Jun; 97(24):2942-4. PubMed ID: 10900877
    [No Abstract]   [Full Text] [Related]  

  • 40. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.